Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems
- PMID: 40980108
- PMCID: PMC12443087
- DOI: 10.3389/fdsfr.2023.1323057
Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems
Abstract
Spontaneous reporting systems remain pivotal for post-marketing surveillance and disproportionality analysis (DA) represents a recognized approach for early signal detection. Although DAs cannot be used per se as a standalone approach to assess a drug-related risk and cannot replace clinical judgment in the individual patient, their role remain irreplaceable for rapid detection of rare and unpredictable adverse drug reactions with strong drug-attributable component (e.g., designated medical events), especially when developed by a multidisciplinary team and combined with a careful case-by-case analysis (individual inspection of reports for causality assessment or to uncover reporting patterns and clinical features). In the recent past, a remarkable increase in publications of pharmacovigilance studies using DAs was observed, albeit the quality was debated: several publications contained "spin", namely, misinterpretation of results to infer causality, calculate incidence, or provide risk stratification, which may ultimately result in unjustified alarm. The development of dedicated Guidelines by the international READUS-PV project (https://readus-statement.org/) will allow reproducible and transparent publication of accurate DAs, thus supporting their real transferability and exploitation by regulators and clinicians. This review offered a perspective on methodological aspects (and understanding) of DAs, their rationale, design, reporting, and interpretation.
Keywords: SDR; adverse drug reactions; disproportionality; disproportionality analyses; signal detection; spontaneous reporting database.
Copyright © 2024 Cutroneo, Sartori, Tuccori, Crisafulli, Battini, Carnovale, Rafaniello, Capuano, Poluzzi, Moretti and Raschi.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Figures
References
-
- Al-Azzawi F., Mahmoud I., Haguinet F., Bate A., Sessa M. (2023). Developing an artificial intelligence-guided signal detection in the food and drug administration adverse event reporting system (FAERS): a proof-of-concept study using galcanezumab and simulated data. Drug Saf. 46 (8), 743–751. 10.1007/s40264-023-01317-0 - DOI - PMC - PubMed
-
- Alkabbani W., Gamble J.-M. (2023). Active-comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: an example using sodium/glucose cotransporter 2 inhibitors. Br. J. Clin. Pharmacol. 89 (2), 431–439. 10.1111/bcp.15178 - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous
